Generex Biotechnology Corp. (GNBT) Develops Chewing Gum Product for Type 2 Diabetes Treatment
Generex Biotechnology Corp. (Nasdaq: GNBT) is a leader in drug delivery for metabolic diseases through the inner lining of the mouth. The company has developed a proprietary Metformin chewing gum product, MetControl. Today, the company announced it produced clinical samples of Metcontrol, manufactured under GMP conditions, to be used in upcoming trials. “We are pleased to have completed this significant milestone with respect to our medicinal chewing gum product," Rose Perri, the company's chief operating officer stated in the press release. “This represents the expansion of the company's proprietary drug delivery platform as it utilizes the core science behind the…